cc 10

CC 1014 is a polypeptide antibiotic isolated from Penicillium lilacinum that inhibits phosphorylation of ADP, Mg ATPase.

4A3-SCC-10是一种可降解的离子型脂质（LDIL），其独特的GSH响应性圆锥形结构使其具有优异的内体逃逸能力以及快速释放mRNA的特性。

LY393615 (NCC1048) 是新型神经元 Ca2+ 与 Na+ 通道阻断剂，具备优良的脑渗透性，并在脑缺血模型中显示神经保护效果，适用于神经性疾病研究。

(S,R,S)-AHPC-C10-NH2 (VH032-C10-NH2) 包含基于 (S,R,S)-AHPC 的VHL 配体和 1 个 linker，是一种合成的 E3 连接酶配体-linker 偶联物 (E3 ligase ligand-linker conjugate)。用于 BET 的靶向 PROTAC 的合成。

MCC1019 is a novel selective inhibitor of the Polo-box domain of Polo-like kinase 1 (PLK1).

(S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-linker 10) 包含基于 (S,R,S)-AHPC 的VHL 配体和 1 个 linker，是一种合成的 E3 连接酶配体-linker 偶联物，用于合成 BET 的靶向 PROTAC。

CC-1088 is an analog of thalidomide with potential antineoplastic activity that belongs to the functional class of agents called selective cytokine inhibitory drugs (SelCIDs). SelCIDs inhibit phosphodiesterase-4 (PDE 4), an enzyme involved in tumor necrosis factor alpha (TNF alpha) production. CC-1088 inhibits production of the cytokines vascular endothelial growth factor (VEGF) (a pro-angiogenic factor) and interleukin-6 (IL-6).

Pulrodemstat HCl 是一种具有口服活性、选择性和高效性的赖氨酸脱甲基酶-1 （LSD1） 抑制剂，也是选择性 KDM1A 抑制剂，具有抗癌抗、增殖活性，抑制 HNSCC 细胞增殖和迁移通过触发细胞凋亡来抑制头颈部鳞状细胞癌的生长。

CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC50=4440 nM). CC-90005 can inhibit T cell activation by IL-2 expression[1]. CC-90005 shows the exquisite selectivity of CC-90005, with IC50s for all other family members of >3 μM[1].CC-90005 is a moderate inhibitor of both CYP2C9 (IC50=8 μM) and CYP2C19 (IC50=5.9 μM) in human liver microsomes[1].CC-90005 inhibits IL-2 expression in LRS_WBC human PBMCs, with an IC50 of 0.15 μM[1].CC-90005 (1-10 μM; 24 h) inhibits T cell proliferation in PBMCs by 51% at 1 μM and 88% at 3 μM[1]. CC-90005 (3-30 mg kg; p.o. twice daily for 4 days) significantly reduces the popliteal lymph node (PLN) size in a model of chronic T cell activation[1].CC-90005 (100 mg kg; a single p.o.) significantly inhibits plasma and spleen IL-2 release by 51 and 54%, respectively[1].CC-90005 exhibits reasonable oral bioavailability (66 and 46%) and Cmax (1.18 and 1.2 μM) following oral administration (10 and 3 mg kg) in rat and dog, respectively[1].CC-90005 exhibits the mean residence time (0.52 and 2.0 h), CL (69.1 and 20.5 mL min kg) and Vss (2.11 and 2.44 L kg) following intravenous administration (2 and 1 mg kg) in rat and dog, respectively[1]. [1]. Papa P, et, al. Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005. J Med Chem. 2021 Aug 26;64(16):11886-11903.

Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact Ki=7.69×104 M-1s-1s).